Background Piperacillin-tazobactam is commonly used in neutropenic sepsis at standard
doses that do not account for inter-individual differences in age, bodyweight and renal …

Objectives To assess population pharmacokinetics (PK) and pharmacodynamics (PD) of
both piperacillin and tazobactam in neutropenia patients and examine dosage requirements …

Objectives The objectives of this study were to describe piperacillin exposure in febrile
neutropenia patients and determine whether therapeutic drug monitoring (TDM) can be …

Background. The empirical treatment of febrile, neutropenic patients with cancer requires
antibacterial regimens active against both gram-positive and gram-negative pathogens. This …

Introduction Patients with febrile neutropenia (FN) exhibit changes in extracellular fluid that
may alter the plasma concentrations of beta-lactams and result in therapeutic failure or …

Purpose Empiric antibiotic monotherapy is considered the standard of treatment for febrile
neutropenic patients with cancer, but this approach may be inadequate because of the …

Goals Efficacy and costs of empirical antibacterial therapy in febrile neutropenic patients are
important issues. Several strategies have been reported to be similarly effective …

We retrospectively evaluated the efficacy and safety of the combination drug piperacillin/
tazobactam (PIPC/TAZ) in comparison with those of fourth-generation cephalosporins (4th …

Changes in the pharmacokinetics of piperacillin in febrile neutropenic patients have been
reported to result in suboptimal exposures. This study aimed to develop a population …

Introduction. Empirical antibiotic therapy in neutropenic patients presenting with fever plays
a significant role in reducing mortality related to infection. Empirical therapies with broad …